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these patients with poor long-term outcome may represent a significantly opportunity to
improve their prognosis.
Table. 
*Adjusted for age, sex, hospital characteristics.
1077-70 Implementation of Acute Myocardial Infarction 
Guidelines in Community Hospitals Without Cardiac 
Catheterization Labs: Are We There Yet?
David M. Larson, Scott W. Sharkey, Barbara T. Unger, Timothy D. Henry, Minneapolis 
Heart Institute Foundation, Minneapolis, MN, Ridgeview Medical Center, Waconia, MN
Background
In order to reduce delays to treatment for ST Elevation Myocardial Infarction (STEMI), the
National Heart Attack Alert Program, in 1993, recommended that emergency depart-
ments (ED) develop protocols for STEMI and monitor quality measures including time to
treatment intervals. The ACC/AHA guidelines on STEMI recommend specific protocols to
rapidly assess and treat STEMI patients. The goal of this study was to obtain information
regarding the current use of STEMI protocols, adherence to guidelines and quality
assessment practices in hospitals without catheterization labs in Minnesota.
Methods
In March 2003, we mailed surveys to ED medical directors or nurse managers in 111
Minnesota hospitals that did not have cardiac catheterization labs. In addition to hospital
size and distance to nearest cath lab, the survey asked the questions regarding proto-
cols, standing orders, quality assurance, decision making and indications for transfer of
pts with STEMI. 
Results
103 (93%) of hospitals surveyed responded (10 to 173 beds; mean 42) located from 12
to 300 miles (mean 74) from the nearest cardiac cath lab. Only 64% of hospitals had
STEMI protocol/guidelines and 45% had standing orders in the ED; 32% had neither. Of
those hospitals that had specific guidelines, only 6% addressed criteria for transfer to a
tertiary hospital. Decisions addressed in guidelines: indications and dose of thrombolyt-
ics (58%), indications and dose of beta blockers (48%), use of aspirin (62%), indications
and dose of heparin (54%), and low molecular weight heparin (23%). Only 50% of hospi-
tals have a formal Quality assessment process for STEMI. Door to drug intervals are
monitored in 53% of hospitals; use of aspirin in 46% and beta blockers in 35%.
Conclusion
Despite recommendations from the NHAAP and ACC/AHA to develop hospital specific
guidelines and protocols for STEMI, only two thirds of community hospitals in Minnesota
have these in place. These guidelines are incomplete and rarely address transfer criteria
to hospitals with PCI capability. Quality performance measurement was lacking in one
half of hospitals surveyed. Programs to help community hospitals develop and implement
guidelines should be encouraged.
1077-71 The Association Between Care and Outcomes in 
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W. Brian Gibler, E. Magnus Ohman, Duke Clinical Research Institute, Durham, NC, 
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Background: Demonstrating the association between adherence to ACC/AHA guide-
lines and better outcomes is an important step in motivating their adoption in clinical
practice. Methods: Using data from the CRUSADE Initiative, we studied 45,987 high-risk
ACS patients (ischemic ST changes and/or positive cardiac markers) treated at 403 US
hospitals between 4/00-4/03. We evaluated hospitals’ use of 9 ACC/AHA Class I care
indicators among eligible patients without contraindications. Hospitals were divided into
quartiles based on overall guidelines adherence, calculated as % of guidelines consistent
care out of total care opportunities. Results: There were significant performance gaps
for each of the 9 indicators between the leading and lagging hospital quartiles: from nar-
row (97 vs 88% for aspirin <24 hrs, p<0.0001) to wide (60 vs 28%, p<0.0001 for GP IIb-
IIIa inhibitors <24 hrs). Compared with lagging, leading centers tended to be larger
(mean bedsize 388 vs 321), more likely academic (34 vs 21%), and to have CABG/PCI
facilities (81 vs 59%, all p<0.001). The Figure displays average in-hospital mortality for
each hospital performance quartile after adjusting for patient and hospital features. Con-
clusion: Adherence to ACC/AHA Guidelines varies markedly among US hospitals. Hos-
pitals with the highest adherence have significantly better patient outcomes than those
less adherent. These data support the need for national ACS quality improvement efforts
designed to promote local change. 
1077-72 Assessment of Glycemic Control in Patients With 
Diabetes Mellitus Admitted With an Acute Coronary 
Syndrome
Darcy Green Conaway, David M. Safley, Philip G. Jones, Jonathan Enriquez, Michelle 
Stephan, John A. Spertus, Mid-America Heart Institute, Kansas City, MO, University of 
Missouri, Kansas City, MO
BACKGROUND:No diabetic patient should be treated for an acute coronary syndrome
(ACS) without also directing attention to their diabetes and its associated metabolic
abnormalities. To understand whether physicians are also attending to patients diabetes
at the time of their ACS, we describe the proportion of diabetic patients who have their
glycemic control assessed during an ACS hospitalization .
METHODS: 968 consecutive patients were prospectively determined to have an ACS.
Prospective chart review and retrospective analyses of laboratory data were performed
to determine whether ACS patients with known diabetes had a glycosylated hemoglobin
(HbA1c) assessed 90 days prior to or during their hospitalization. We also examined
whether patient characteristics or processes of care were associated with HbA1c assess-
ments.
RESULTS: Among diabetic ACS patients (n=235, 24%), HbA1c values were obtained in
163 (69%). Older patients were less likely than younger patients to have had an HbA1c
checked (60% of patients >/=70 vs. 67% for ages 60-69 vs. 79% for ages <60, p=0.02).
Of the 235 diabetic patients, 89 had an endocrinology consultation. Of the 59 patients
who received an endocrine consult without a prior HbA1c, 54 (92%) had one checked
after the consult. Of the 146 patients not receiving an endocrine consult, HbA1c values
were checked in 79 (54%, p<0.001 compared to those who had a consult). The admitting
blood sugars of patients without a consult or HgA1c were elevated (161±60 mg/dL; >200
mg/dL in 25% of patients).
CONCLUSIONS: Almost a third of known diabetics have no recent evaluation of their gly-
cemic control prior to or during an ACS admission. Older age and no endocrinology con-
sultation are associated with less frequent assessments of HbA1c. These data suggest
an important opportunity to improve diabetes care at the time of an ACS.
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Background: Utilization of angiotensin converting enzyme inhibitors (ACE-I) and beta-
adrenergic receptor blockers (BB) in heart failure (HF) patients remain suboptimal
despite the results of clinical trials and evidence-based guidelines supporting their
use.This report provides the results of a collaborative quality improvement program for
HF care implemented in managed Medicare and Medicaid programs in North Carolina.
Methods: Managed care plans identified adult patients with HF during 2000 (pre-inter-
vention) and from November 1, 2001 through October 31, 2002 (post-intervention). A
stratified random sample of patients’ outpatient medical records were reviewed by trained
nurse abstractors to obtain data regarding type of heart failure, demographics, comorbid-
ities, and therapies. The intervention consisted of guideline summary dissemination, per-
formance audit with feedback, patient-specific chart reminders and patient activation
mailings.
Results: We sampled 1613 patients from 5 plans during the pre-intervention period and
1528 patients during the post-intervention period. Assessment of left ventricular function
increased from 81.7% to 85.3% of patients (p < 0.0001). Among patients with moderate
to severe left ventricular systolic dysfunction, there was no substantive change in treat-
ment with ACE inhibitors or vasodilators; whereas, appropriate treatment with beta block-
ers increased from 48.3% (with another 11.9% with documented contraindications) to
67.9% (with another 7.5% with documented contraindications). The quality gap
decreased from 39.8% to 24.6% (p < 0.0001).
Conclusion: Left ventricular function assessment improved despite high pre-intervention
rates. Treatment rates with ACE-I and vasodilators remained high, but did not improve.
Treatment rates with BB improved substantially translating into a significant public health
benefit. Given published data regarding benefits of BB, one might expect 50 fewer deaths
Diabetic 
Patients
Non-
Diabetic 
Patients
Adjusted Odds Ratio Diabetic/
Non-Diabetic (95% CI)*
Medications at within 6 
hrs of Admission, (%)
Aspirin 69 78 0.71 (0.61, 0.84)
Beta Blockers 25 33 0.77 (0.64, 0.92)
Medications at Discharge 
, (%)
Aspirin 80 86 0.67 (0.57, 0.79)
Beta Blockers 75 80 0.79 (0.66, 0.94)
ACE inhibitors 75 69 1.34 (1.05, 1.71)
Statins 56 63 0.86 (0.63, 1.18)
